Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administration.

New evidence suggests that mass drug administration of azithromycin (MDAA) can significantly reduce childhood mortality in high-burden, low-resource settings, yet the World Health Organization's (WHO) 2020 guidelines take a cautious approach due to concerns about antimicrobial resistance (AMR).While...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maple Goh, A M Viens, Safura Abdool Karim, Aaron S Kesselheim, Kevin Outterson
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2025-09-01
coleção:	PLoS Medicine
Acesso em linha:	https://doi.org/10.1371/journal.pmed.1004736
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!